

Special Issue

Vaccine Development for Toxoplasmosis

Message from the Guest Editor

Toxoplasmosis is a disease caused by *Toxoplasma gondii*, exerting a high impact on human health worldwide. This disease may affect immunocompromised individuals causing serious health issues such as encephalitis, pneumonia and even death. Current treatment options are old, limited, and possess toxic side effects. At present, no vaccine exists to prevent human disease caused by *T. gondii*, thus demand for a vaccine presenting complete and lasting protection against toxoplasmosis is urgent. This research topic will include contributions that highlight advances and challenges regarding the development of a novel prophylactic vaccine for toxoplasmosis. Research areas in this field may include (but are not limited to) the following: nanovaccines development; establishment of *in vitro* and/or *in vivo* study models; immune responses; nasal immunization; identification of immune mechanisms induced by vaccination and related to protection against infection; vaccines in congenital toxoplasmosis. I am pleased to invite you to contribute with original research articles or reviews.

Guest Editor

Dr. Margarida Borges

UCIBIO/REQUIMTE, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal

Deadline for manuscript submissions

closed (30 September 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/114518

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).